TY - JOUR
T1 - Development of a doxepin-loaded chitosan nanogel as an innovative nano platform for oral mucositis treatment
AU - Samiraninezhad, Nazafarin
AU - Asadi, Khatereh
AU - Heidari, Reza
AU - Rezaee, Mostafa
AU - Gholami, Ahmad
AU - Amini, Abbas
PY - 2025
Y1 - 2025
N2 - Oral mucositis is a prevalent complication in patients undergoing chemotherapy. This study aimed to develop and characterize a doxepin-loaded chitosan nanogel (DX-CN) as a topical treatment option. DX-CN and chitosan nanogel (CN) were synthesized using ionic gelation and characterized by Fourier transform infrared spectroscopy (FTIR) and field emission scanning electron microscopy (FESEM). FTRI confirmed the spectral compatibility of DX-CN. The nanogels exhibited spherical morphology. Particle sizes were 322.7 nm for DX-CN and 302.8 nm for CN. Polydispersity indices (PdI) were 0.732 for DX-CN and 0.51 for CN. Zeta potentials (ZP) were +52.7 mV for DX-CN and +52.8 mV for CN. In vitro assays included drug loading capacity (96.2 % for DX-CN), drug release profile (83.39 % cumulative release over 10 h), cytotoxicity, and antioxidative effects. DX-CN exhibited significant cytocompatibility with human umbilical vein endothelial cells (HUVEC) and selective cytotoxicity against oral squamous cell carcinoma (OSCC) cells. Furthermore, DX-CN demonstrated reduced oxidative stress, as indicated by lower lipid peroxidation, lactate dehydrogenase leakage, and reactive oxygen species formation compared to doxepin alone. The findings suggest that DX-CN, with its efficient drug loading, sustained release, and targeted biocompatibility, holds promise as a therapeutic platform for the topical treatment of chemotherapy-induced oral mucositis.
AB - Oral mucositis is a prevalent complication in patients undergoing chemotherapy. This study aimed to develop and characterize a doxepin-loaded chitosan nanogel (DX-CN) as a topical treatment option. DX-CN and chitosan nanogel (CN) were synthesized using ionic gelation and characterized by Fourier transform infrared spectroscopy (FTIR) and field emission scanning electron microscopy (FESEM). FTRI confirmed the spectral compatibility of DX-CN. The nanogels exhibited spherical morphology. Particle sizes were 322.7 nm for DX-CN and 302.8 nm for CN. Polydispersity indices (PdI) were 0.732 for DX-CN and 0.51 for CN. Zeta potentials (ZP) were +52.7 mV for DX-CN and +52.8 mV for CN. In vitro assays included drug loading capacity (96.2 % for DX-CN), drug release profile (83.39 % cumulative release over 10 h), cytotoxicity, and antioxidative effects. DX-CN exhibited significant cytocompatibility with human umbilical vein endothelial cells (HUVEC) and selective cytotoxicity against oral squamous cell carcinoma (OSCC) cells. Furthermore, DX-CN demonstrated reduced oxidative stress, as indicated by lower lipid peroxidation, lactate dehydrogenase leakage, and reactive oxygen species formation compared to doxepin alone. The findings suggest that DX-CN, with its efficient drug loading, sustained release, and targeted biocompatibility, holds promise as a therapeutic platform for the topical treatment of chemotherapy-induced oral mucositis.
KW - Chitosan
KW - Doxepin
KW - Nanoparticle drug delivery system
KW - Oral ulcer
KW - Stomatitis
UR - http://www.scopus.com/inward/record.url?scp=85210627679&partnerID=8YFLogxK
UR - https://ezproxy.uws.edu.au/login?url=https://doi.org/10.1016/j.jddst.2024.106430
U2 - 10.1016/j.jddst.2024.106430
DO - 10.1016/j.jddst.2024.106430
M3 - Article
AN - SCOPUS:85210627679
SN - 1773-2247
VL - 104
JO - Journal of Drug Delivery Science and Technology
JF - Journal of Drug Delivery Science and Technology
M1 - 106430
ER -